Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation

Toxicology in Vitro

Volumn 28, Issue 3, 2014, Pages 419-425

  Liu, Ningning ^a   Huang, Hongbiao ^a   Liu, Shouting ^a   Li, Xiaofen ^a   Yang, Changshan ^a   Dou, Q Ping ^a,b   Liu, Jinbao ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer therapy; CYP1A2; Gambogic acid; Proteasome; Ubiquitin proteasome system; Verapamil

Indexed keywords

ACETYLCYSTEINE; CASPASE; GAMBOGIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; REACTIVE OXYGEN METABOLITE; VERAPAMIL;

APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CELL STRAIN K 562; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; WESTERN BLOTTING;

APOPTOSIS; CANCER THERAPY; CYP1A2; GAMBOGIC ACID; PROTEASOME; UBIQUITIN-PROTEASOME SYSTEM; VERAPAMIL;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CASPASES; CELL DEATH; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; HEP G2 CELLS; HUMANS; K562 CELLS; PROTEASOME INHIBITORS; REACTIVE OXYGEN SPECIES; VERAPAMIL; XANTHONES;

EID: 84892656473     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.12.008     Document Type: Article

References (35)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
2. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59:2615-2622.
3. Auterhoff H., Frauendorf H., Liesenklas W., Schwandt C. The chief constituents of gamboge resins. 1. Chemistry of gamboge. Arch. Pharm. 1962, 295(67):833-846.
4. Chen Z., Romaguera J., Wang M., Fayad L., Kwak L.W., McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br. J. Haematol. 2012, 159:243-246.
5. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989, 58:137-171.
6. Finucane D.M., Bossy-Wetzel E., Waterhouse N.J., Cotter T.G., Green D.R. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J. Biol. Chem. 1999, 274:2225-2233.
7. Fribley A., Zeng Q., Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 2004, 24:9695-9704.
8. Fuhr U., Woodcock B.G., Siewert M. Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2. Eur. J. Clin. Pharmacol. 1992, 42:463-464.
9. Huang H., Zhang X., Li S., Liu N., Lian W., McDowell E., Zhou P., Zhao C., Guo H., Zhang C., Yang C., Wen G., Dong X., Lu L., Ma N., Dong W., Dou Q.P., Wang X., Liu J. Physiological levels of ATP negatively regulate proteasome function. Cell Res. 2010, 20:1372-1385.
10. Huang H., Chen D., Li S., Li X., Liu N., Lu X., Liu S., Zhao K., Zhao C., Guo H., Yang C., Zhou P., Dong X., Zhang C., Guanmei, Dou Q.P., Liu J. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011, 301:221-228.
11. Huang H., Liu N., Zhao K., Zhu C., Lu X., Li S., Lian W., Zhou P., Dong X., Zhao C., Guo H., Zhang C., Yang C., Wen G., Lu L., Li X., Guan L., Liu C., Wang X., Dou Q.P., Liu J. Sanggenon C decreases tumor cell viability associated with proteasome inhibition. Front. Biosci. (Elite Ed) 2011, 3:1315-1325.
12. Huang H., Liu N., Guo H., Liao S., Li X., Yang C., Liu S., Song W., Liu C., Guan L., Li B., Xu L., Zhang C., Wang X., Dou Q.P., Liu J. l-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PLoS One 2012, 7:e49062.
13. Kane R.C., Farrell A.T., Sridhara R., Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 2006, 12:2955-2960.
14. Kasibhatla S., Jessen K.A., Maliartchouk S., Wang J.Y., English N.M., Drewe J., Qiu L., Archer S.P., Ponce A.E., Sirisoma N., Jiang S., Zhang H.Z., Gehlsen K.R., Cai S.X., Green D.R., Tseng B. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc. Natl. Acad. Sci. USA 2005, 102:12095-12100.
15. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA 2000, 97:3850-3855.
16. Li X., Liu S., Huang H., Liu N., Zhao C., Liao S., Yang C., Liu Y., Zhao C., Li S., Lu X., Liu C., Guan L., Zhao K., Shi X., Song W., Zhou P., Dong X., Guo H., Wen G., Zhang C., Jiang L., Ma N., Li B., Wang S., Tan H., Wang X., Dou Q.P., Liu J. Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Rep. 2013, 3:211-222.
17. Liu W., Guo Q.L., You Q.D., Zhao L., Gu H.Y., Yuan S.T. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J. Gastroenterol. 2005, 11:3655-3659.
18. McCullough K.D., Martindale J.L., Klotz L.O., Aw T.Y., Holbrook N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 2001, 21:1249-1259.
19. Meister S., Frey B., Lang V.R., Gaipl U.S., Schett G., Schlotzer-Schrehardt U., Voll R.E. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia 2010, 12:550-561.
20. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M., Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
21. Orlowski R.Z., Dees E.C. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003, 5:1-7.
22. Pandey M.K., Sung B., Ahn K.S., Kunnumakkara A.B., Chaturvedi M.M., Aggarwal B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007, 110:3517-3525.
23. Panthong A., Norkaew P., Kanjanapothi D., Taesotikul T., Anantachoke N., Reutrakul V. Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from Garcinia hanburyi Hook f. J. Ethnopharmacol. 2007, 111:335-340.
24. Rong J.J., Hu R., Qi Q., Gu H.Y., Zhao Q., Wang J., Mu R., You Q.D., Guo Q.L. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett. 2009, 284:102-112.
25. Shi X., Chen X., Li X., Lan X., Zhao C., Liu S., Huang H., Liu N., Liao S., Song W., Zhou P., Wang S., Xu L., Wang X., Dou Q.P., Liu J. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-abl downregulation. Clin. Cancer Res. 2013, 19. 10.1158/1078-0432.CCR-13-1063.
26. Simon H.U., Haj-Yehia A., Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5:415-418.
27. Sun X.M., Butterworth M., MacFarlane M., Dubiel W., Ciechanover A., Cohen G.M. Caspase activation inhibits proteasome function during apoptosis. Mol. Cell 2004, 14:81-93.
28. Wu Z.Q., Guo Q.L., You Q.D., Zhao L., Gu H.Y. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol. Pharm. Bull. 2004, 27:1769-1774.
29. Xu X., Liu Y., Wang L., He J., Zhang H., Chen X., Li Y., Yang J., Tao J. Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells. Int. J. Dermatol. 2009, 48:186-192.
30. Yang Y., Yang L., You Q.D., Nie F.F., Gu H.Y., Zhao L., Wang X.T., Guo Q.L. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 2007, 256:259-266.
31. Yang H., Zonder J.A., Dou Q.P. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin. Invest. Drugs 2009, 18:957-971.
32. Yi T., Yi Z., Cho S.G., Luo J., Pandey M.K., Aggarwal B.B., Liu M. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008, 68:1843-1850.
33. Yu J., Guo Q.L., You Q.D., Zhao L., Gu H.Y., Yang Y., Zhang H.W., Tan Z., Wang X. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 2007, 28:632-638.
34. Zhao C., Liu S., Yang C., Li X., Huang H., Liu N., Li S., Wang X., Liu J. Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-κB pathway. Am. J. Cardiovasc. Dis. 2013, 3:135-145.
35. Zhou Z.T., Wang J.W. Phase I human tolerability trial of gambogic acid. Chin. J. New Drugs 2007, 16:79-82.